Ongoing positive effect of platelet-rich plasma versus @entity228 injection in XXXX : a double-blind randomized controlled trial with 2-year follow-up.

@entity1 @entity1423 @entity228 @entity2633 @entity158
BACKGROUND: @entity1423 ( @entity1423 ) has been shown to be a general stimulation for repair and 1-year results showed promising success percentages. PURPOSE: This trial was undertaken to determine the effectiveness of @entity1423 compared with @entity228 injections in @entity1 with chronic @entity2633 with a 2-year follow-up. STUDY DESIGN: Randomized controlled trial; Level of evidence, 1. METHODS: The trial was conducted in 2 Dutch teaching hospitals. One hundred @entity1 with chronic @entity2633 were randomly assigned to a leukocyte-enriched @entity1423 group (n = 51) or the @entity228 group (n = 49). Randomization and allocation to the trial group were carried out by a central computer system. @entity1 received either a @entity228 injection or an autologous platelet concentrate injection through a peppering needling technique. The primary analysis included visual analog scale (VAS) @entity158 scores and Disabilities of the Arm, Shoulder and Hand (DASH) outcome scores. RESULTS: The @entity1423 group was more often successfully treated than the @entity228 group (P < .0001). Success was defined as a reduction of 25% on VAS or DASH scores without a reintervention after 2 years. When baseline VAS and DASH scores were compared with the scores at 2-year follow-up, both groups significantly improved across time (intention-to-treat principle). However, the DASH scores of the @entity228 group returned to baseline levels, while those of the @entity1423 group significantly improved (as-treated principle). There were no complications related to the use of @entity1423 . CONCLUSION: Treatment of @entity1 with chronic @entity2633 with @entity1423 reduces @entity158 and increases function significantly, exceeding the effect of @entity228 injection even after a follow-up of 2 years. Future decisions for application of @entity1423 for @entity2633 should be confirmed by further follow-up from this trial and should take into account possible costs and harms as well as benefits.
